Australia markets close in 52 minutes

Genetic Technologies Limited (GTG.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1350+0.0150 (+12.50%)
As of 02:05PM AEST. Market open.
Full screen
Previous close0.1200
Open0.1250
Bid0.1300 x 10000000
Ask0.1350 x 249000000
Day's range0.1250 - 0.1350
52-week range0.0930 - 0.1850
Volume25,907
Avg. volume80,096
Market cap17.849M
Beta (5Y monthly)0.37
PE ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings date23 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees

    MELBOURNE, Australia, May 06, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the execution of a strategic joint sales & marketing agreement with US based Wellworks for You Inc. (Wellworks). As part of the agreement, Wellworks will incorporate the geneType portfolio of tests into its fully flexible, scalable employee wellness solutions for orga

  • GlobeNewswire

    Appendix 4C & Quarterly Business Update – March 2024

    Launching our most comprehensive test and expanding into new global marketsMELBOURNE, Australia, April 30, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 30 March 2024 (Q3 FY24). Key highlights: Cash Receipts totalling A$1.8m for the quarter ending March 2024.Launched tar

  • GlobeNewswire

    Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

    MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Comp